Setback for an Alzheimer's disease vaccine: lessons learned.
Mathews
Paul M
PM
Nixon
Ralph A
RA
D000544:Alzheimer Disease / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*; D023582:Alzheimer Vaccines / Q000009:adverse effects*; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors / Q000276:immunology*; D000818:Animals; D001812:Blood-Brain Barrier / Q000276:immunology; D002556:Cerebrospinal Fluid Proteins / Q000134:cerebrospinal fluid; D003072:Cognition Disorders / Q000276:immunology; D004195:Disease Models, Animal; D018450:Disease Progression; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000134:cerebrospinal fluid; D007167:Immunotherapy / Q000009:adverse effects; D008264:Macrophages / Q000276:immunology / Q000473:pathology; D008590:Meningoencephalitis / Q000209:etiology* / Q000276:immunology; D051379:Mice; D016874:Neurofibrillary Tangles / Q000473:pathology; D058225:Plaque, Amyloid / Q000276:immunology / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D002556:Cerebrospinal Fluid Proteins; D007074:Immunoglobulin G